$CAPR
CAPRICOR THERAPEUTICS, INC.

2022 Q4 Form 10-Q Financial Statement

#000155837022017470 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $2.600M $1.592M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.794M $2.565M
YoY Change 32.06% 42.45%
% of Gross Profit
Research & Development $6.232M $5.500M
YoY Change 485.96% 120.0%
% of Gross Profit
Depreciation & Amortization $191.6K $137.0K
YoY Change 143.61% 111.73%
% of Gross Profit
Operating Expenses $9.026M $8.069M
YoY Change 183.88% 87.03%
Operating Profit -$6.478M
YoY Change 50.14%
Interest Expense $379.7K $106.6K
YoY Change 2276.1% 584.91%
% of Operating Profit
Other Income/Expense, Net $0.00 $106.6K
YoY Change -100.0% -72.14%
Pretax Income -$7.721M -$6.371M
YoY Change 24.72% 62.04%
Income Tax
% Of Pretax Income
Net Earnings -$7.721M -$6.371M
YoY Change 24.72% 62.04%
Net Earnings / Revenue -296.96% -400.3%
Basic Earnings Per Share -$0.26
Diluted Earnings Per Share -$0.31 -$0.26
COMMON SHARES
Basic Shares Outstanding 25.24M 24.35M
Diluted Shares Outstanding 24.43M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.42M $46.61M
YoY Change 18.74% 14.14%
Cash & Equivalents $9.603M $8.414M
Short-Term Investments $31.82M $38.20M
Other Short-Term Assets $919.9K $343.7K
YoY Change -20.7% 23.22%
Inventory
Prepaid Expenses
Receivables $547.6K $547.6K
Other Receivables $0.00 $0.00
Total Short-Term Assets $42.89M $47.50M
YoY Change 17.71% 15.03%
LONG-TERM ASSETS
Property, Plant & Equipment $4.588M $3.591M
YoY Change 155.5% 137.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $268.2K $268.2K
YoY Change -2.74% -7.11%
Total Long-Term Assets $7.206M $6.423M
YoY Change 47.26% 256.4%
TOTAL ASSETS
Total Short-Term Assets $42.89M $47.50M
Total Long-Term Assets $7.206M $6.423M
Total Assets $50.09M $53.93M
YoY Change 21.21% 25.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.924M $3.937M
YoY Change 32.51% 31.73%
Accrued Expenses $682.0K $697.6K
YoY Change 63.31%
Deferred Revenue $17.98M $18.60M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.59M $23.19M
YoY Change 470.63% 676.18%
LONG-TERM LIABILITIES
Long-Term Debt $3.376M $3.376M
YoY Change 0.0% 0.0%
Other Long-Term Liabilities $11.35M $11.93M
YoY Change 362.59%
Total Long-Term Liabilities $14.72M $15.31M
YoY Change 152.57% 353.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.59M $23.19M
Total Long-Term Liabilities $14.72M $15.31M
Total Liabilities $38.31M $38.50M
YoY Change 284.54% 504.94%
SHAREHOLDERS EQUITY
Retained Earnings -$137.1M -$129.4M
YoY Change 26.85% 26.98%
Common Stock $148.8M $144.7M
YoY Change 6.69% 4.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.79M $15.43M
YoY Change
Total Liabilities & Shareholders Equity $50.09M $53.93M
YoY Change 21.21% 25.12%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$7.721M -$6.371M
YoY Change 24.72% 62.04%
Depreciation, Depletion And Amortization $191.6K $137.0K
YoY Change 143.61% 111.73%
Cash From Operating Activities -$6.902M -$5.686M
YoY Change 22.65% 70.33%
INVESTING ACTIVITIES
Capital Expenditures $1.222M -$1.099M
YoY Change -431.6% 134.77%
Acquisitions
YoY Change
Other Investing Activities $6.365M -$3.077M
YoY Change
Cash From Investing Activities $5.142M -$4.177M
YoY Change -1494.77% 791.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.950M 1.882M
YoY Change 6861.36% -71.35%
NET CHANGE
Cash From Operating Activities -6.902M -5.686M
Cash From Investing Activities 5.142M -4.177M
Cash From Financing Activities 2.950M 1.882M
Net Change In Cash 1.190M -7.980M
YoY Change -119.98% -389.02%
FREE CASH FLOW
Cash From Operating Activities -$6.902M -$5.686M
Capital Expenditures $1.222M -$1.099M
Free Cash Flow -$8.125M -$4.586M
YoY Change 54.49% 59.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24346775
dei Trading Symbol
TradingSymbol
CAPR
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24431787
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23095375
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22731638
dei Entity Central Index Key
EntityCentralIndexKey
0001133869
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24702684
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24185001
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24702684
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34058
dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150, San Diego
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
727-1755
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25241402
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8413653
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34885274
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
84156
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
599388
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
38199859
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2022Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
547580
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
391750
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
343684
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1159937
CY2022Q3 us-gaap Assets Current
AssetsCurrent
47504776
CY2021Q4 us-gaap Assets Current
AssetsCurrent
36436961
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3591397
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1795696
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2563762
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2821944
CY2022Q3 us-gaap Other Assets
OtherAssets
268172
CY2021Q4 us-gaap Other Assets
OtherAssets
275722
CY2022Q3 us-gaap Assets
Assets
53928107
CY2021Q4 us-gaap Assets
Assets
41330323
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3852356
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3116371
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
697561
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
417632
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18560430
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23194503
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4133391
CY2022Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2021Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2082849
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2452707
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9848004
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
15307112
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5828966
CY2022Q3 us-gaap Liabilities
Liabilities
38501615
CY2021Q4 us-gaap Liabilities
Liabilities
9962357
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24702684
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24185001
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
24703
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
24185
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
144638221
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
139404060
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
122467
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129358899
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108060279
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
15426492
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53928107
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41330323
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1591566
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1591566
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
244898
CY2022Q3 us-gaap Revenues
Revenues
1591566
us-gaap Revenues
Revenues
1591566
us-gaap Revenues
Revenues
244898
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5504356
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2513915
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15585143
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9307512
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2564960
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1800630
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7637461
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5496186
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8069316
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
4314545
us-gaap Operating Expenses
OperatingExpenses
23222604
us-gaap Operating Expenses
OperatingExpenses
14803698
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6477750
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4314545
us-gaap Operating Income Loss
OperatingIncomeLoss
-21631038
us-gaap Operating Income Loss
OperatingIncomeLoss
-14558800
CY2021Q3 us-gaap Other Income
OtherIncome
367168
us-gaap Other Income
OtherIncome
190582
us-gaap Other Income
OtherIncome
367168
CY2022Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
106635
CY2021Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
15570
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
141836
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
41476
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
318160
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
106635
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
382738
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
332418
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
726804
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6371115
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3931807
us-gaap Net Income Loss
NetIncomeLoss
-21298620
us-gaap Net Income Loss
NetIncomeLoss
-13831996
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
99637
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22731638
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
31367966
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
122467
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6271478
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3931807
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21176153
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13831996
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24431787
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23095375
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24346775
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1065329
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27465
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7818094
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
24642666
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1157904
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15006
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22830
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7109411
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
18728995
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1880324
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1087133
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1518
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
99637
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6371115
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
15426492
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28199784
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12578526
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
752962
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1436
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5151923
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
36380785
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1035312
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
712299
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4748266
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
33380130
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6562153
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
720281
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5213
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3931807
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
36735970
us-gaap Profit Loss
ProfitLoss
-21298620
us-gaap Profit Loss
ProfitLoss
-13831996
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
341529
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
167052
us-gaap Share Based Compensation
ShareBasedCompensation
3310366
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11181741
capr Noncash Lease Expenses
NoncashLeaseExpenses
0
capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
155830
capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
180178
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-816253
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
318160
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-732300
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-7550
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
200000
capr Noncash Lease Expenses
NoncashLeaseExpenses
168254
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
735985
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-224409
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-515232
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
488108
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
28408434
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11818689
us-gaap Share Based Compensation
ShareBasedCompensation
2185542
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
82175353
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
44097961
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1306199
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
827615
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
831032
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40214623
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-827615
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1880324
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20175991
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
43989
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6649
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1924313
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20182640
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-26471621
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8173284
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34885274
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32665874
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8413653
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40839158
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
34900000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
30000000.0
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</p>
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
46600000
CY2020Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191199
CY2022Q3 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
547580
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
us-gaap Depreciation
Depreciation
341529
us-gaap Depreciation
Depreciation
164887
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4671000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2552408
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1079603
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
756712
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3591397
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1795696
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5500000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2500000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15600000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9300000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6300000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3900000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21200000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13800000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6059552
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3968546
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
318160
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
capr Commission Rate On Sale Price Per Share
CommissionRateOnSalePricePerShare
0.030
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24702684
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2021Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2022Q3 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
1.37
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105782
capr Share Based Compensation Number Of Plans
ShareBasedCompensationNumberOfPlans
5
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
269731
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
710142
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2500000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
823084
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3500000
CY2021Q2 capr Sharebased Compensation Arrangement By Sharebased Payment Award Percentage Of Annual Increase In Number Of Shares Authorized
SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfAnnualIncreaseInNumberOfSharesAuthorized
0.05
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1209250
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2642241
capr Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock
MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock
100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.41
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.03
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.24
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.015
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.005
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.011
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1087133
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
720281
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3310366
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2185542
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1600000
CY2022Q3 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2022Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
46300000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
196588
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
790922
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
755815
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
699848
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
539821
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2982994
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
202584
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2780410
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
697561
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2082849
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2780410
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M29D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0361
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2600000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2800000
capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2022Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1600000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30000000.0
CY2022Q1 capr Potential Milestone Payments
PotentialMilestonePayments
705000000.0
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30000000.0
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30000000.0
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18600000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9800000
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
84156
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
599388
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
1700000
us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
245000

Files In Submission

Name View Source Status
0001558370-22-017470-index-headers.html Edgar Link pending
0001558370-22-017470-index.html Edgar Link pending
0001558370-22-017470.txt Edgar Link pending
0001558370-22-017470-xbrl.zip Edgar Link pending
capr-20220930.xsd Edgar Link pending
capr-20220930x10q.htm Edgar Link pending
capr-20220930xex31d1.htm Edgar Link pending
capr-20220930xex31d2.htm Edgar Link pending
capr-20220930xex32d1.htm Edgar Link pending
capr-20220930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
capr-20220930_def.xml Edgar Link unprocessable
capr-20220930_lab.xml Edgar Link unprocessable
capr-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
capr-20220930_cal.xml Edgar Link unprocessable
capr-20220930x10q_htm.xml Edgar Link completed